KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Baptist Health South Florida
Università Vita-Salute San Raffaele
University of Kentucky
Weill Medical College of Cornell University
Genelux Corporation
Fox Chase Cancer Center
Mereo BioPharma
Heat Biologics
Novartis
The Netherlands Cancer Institute
University of Pittsburgh
Hellenic Oncology Research Group
University of Pittsburgh
Sun Yat-sen University
Hellenic Oncology Research Group
Eli Lilly and Company
Eli Lilly and Company